Recently, a TCR-mimic monoclonal antibody that could target a range of phospho-neoantigens displayed by HLA-A*02:01 in various tumor cells has been generated and has shown the capacity to induce T cells to kill tumor cells. Here, HLA-A is linked to neoplasm.